First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial
-
Published:2024-09
Issue:
Volume:107
Page:105275
-
ISSN:2352-3964
-
Container-title:eBioMedicine
-
language:en
-
Short-container-title:eBioMedicine
Author:
Poh Xuan YingORCID, Lee I. Russel, Tan Chee Wah, Chavatte Jean-MarcORCID, Fong Siew Wai, Goh Yun Shan, Rouers Angeline, Wong Nathan, Torres-Ruesta Anthony, Mah Shirley Y.Y., Yeoh Aileen Y.Y., Gandhi Mihir, Rahman Nabilah, Chin Yi Qing, Lim J. Jonathan, Yoong Terence J.K., Rao Suma, Chia Po Ying, Ong Sean W.X., Lee Tau Hong, Sadarangani Sapna P., Lin Ray J.H., Lim Daniel R.X., Chia Wanni, Renia Laurent, Ren Ee Chee, Lin Raymond T.P., Lye David C., Wang Lin-Fa, Ng Lisa F.P., Young Barnaby E.
Funder
National Medical Research Council
|
|